Editorial: Withdrawal of sibutramine for weight loss: Where does this leave clinicians?

Obesity Facts

Volumn 3, Issue 3, 2010, Pages 155-156

  Czernichow, Sébastien ^a,b,c   Batty, David ^d,e  

^a INRA CNAM UP13 ^*  (France)

^b AVICENNE HOSPITAL   (France)

^c UNIVERSITÉ PARIS 13   (France)

^d MEDICAL RESEARCH COUNCIL   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LIRAGLUTIDE; SIBUTRAMINE; TETRAHYDROLIPSTATIN; ANOREXIGENIC AGENT; CYCLOBUTANE DERIVATIVE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG EFFECT; DRUG WITHDRAWAL; EDITORIAL; HUMAN; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; TREATMENT OUTCOME; VOMITING; WEIGHT REDUCTION; DRUG APPROVAL; RISK FACTOR;

APPETITE DEPRESSANTS; CYCLOBUTANES; DRUG APPROVAL; HUMANS; OBESITY; RISK FACTORS;

EID: 77954528310     PISSN: 16624025     EISSN: 16624033     Source Type: Journal    
DOI: 10.1159/000316508     Document Type: Editorial

References (18)

1. Haslam DW, James WP: Obesity. Lancet 2005;366 (9492):1197-1209.
2. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM: Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006;295(13):1549-1555.
3. Czernichow S, Vergnaud AC, Maillard-Teyssier L, Peneau S, Bertrais S, Mejean C, et al: Trends in the prevalence of obesity in employed adults in central-western France: a population-based study, 1995-2005. Prev Med 2009;48(3):262-266.
4. Charafeddine R, Van Oyen H, Demarest S: Trends in social inequalities in obesity: Belgium, 1997 to 2004. Prev Med 2009;48(1):54-58.
5. Peneau S, Salanave B, Maillard-Teyssier L, Rolland-Cachera MF, Vergnaud AC, Mejean C, et al: Prevalence of overweight in 6- to 15-year-old children in central/western France from 1996 to 2006: trends toward stabilization. Int J Obes (Lond) 2009; 33(4):401-407.
6. Hercberg S, Chat-Yung S, Chauliac M: The French National Nutrition and Health Program: 2001 - 2006- 2010. Int J Public Health 2008;53:68-77.
7. Shaw K, Gennat H, O'Rourke P, Del Mar C: Exercise for overweight or obesity. Cochrane Database Syst Rev 2006;(4):CD003817.
8. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L: XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27(1):155-161. (Pubitemid 38196725)
9. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rössner S: Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005;365(9468):1389-1397. (Pubitemid 40523733)
10. James WP, Astrup A, Finer N, Hilsted J, Kopelman P, Rössner S, et al: Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000;356(9248):2119-2125.
11. Rucker D, Padwal R, Li SK, Curioni C, Lau DC: Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007;335 (7631):1194-1199.
12. Lloret-Linares C, Greenfield JR, Czernichow S: Effect of weight-reducing agents on glycaemic parameters and progression to type 2 diabetes: a review. Diabet Med 2008;25(10):1142-1150.
13. Czernichow S, Lee CM, Barzi F, Greenfield JR, Baur LA, Chalmers J, et al: Efficacy of weight loss drugs on obesity and cardiovascular risk factors in obese adolescents: a meta-analysis of randomized controlled trials. Obes Rev 2010;11(2):150-158.
14. Caterson I, Coutinho W, Finer N, Van Gaal L, Maggioni A, Torp-Pedersen C, et al: Early response to sibutramine in patients not meeting current label criteria: preliminary analysis of SCOUT lead-in period. Obesity (Silver Spring) 2010;18(5): 987-994.
15. Torp-Pedersen C, Caterson I, Coutinho W, Finer N, Van Gaal L, Maggioni A, et al: Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. Eur Heart J 2007;28(23):2915-2923.
16. Van Gaal LF, Caterson ID, Coutinho W, Finer N, Maggioni AP, Sharma AM, et al: Weight and blood pressure response to weight management and sibutramine in diabetic and non-diabetic high-risk patients: an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes (SCOUT) trial. Diabetes Obes Metab 2010;12(1):26-34.
17. Williams G: Withdrawal of sibutramine in Europe. BMJ 2010;340:c824.
18. Astrup A, Rössner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, et al: Effects of liraglutide in the treatment of obesity: a randomised, double- blind, placebo-controlled study. Lancet 2009; 374(9701):1606-1616.